Migraine prophylaxis: investigational agents
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
Migraine prophylaxis: investigational agents. PACAP is pituitary adenylate cyclase-activating polypeptide. Fully referenced neurology checklist.
PACAP pathway
- PACAP is pituitary adenylate cyclase-activating polypeptide
- It is a vasoactive peptide
- It selectively activates the PAC1 receptor
- PACAP plays a role in migraine pathophysiology independent from CGRP
PACAP pathway modulators
Locked: subscribe to see this section.
Other pathways
Locked: subscribe to see this section.
References
- Ashina M, Phul R, Khodaie M, Löf E, Florea I. A monoclonal antibody to PACAP for migraine prevention. N Engl J Med 2024; 391:800-809.
- Ashina H, Christensen RH, Hay DL, et al. Pituitary adenylate cyclase-activating polypeptide signalling as a therapeutic target in migraine. Nat Rev Neurol 2024; 20:660-670.
- Schytz HW, Olesen J, Ashina M. The PACAP receptor: a novel target for migraine treatment. Neurotherapeutics 2010; 7:191-196.
- Kuburas A, Russo AF. Shared and independent roles of CGRP and PACAP in migraine pathophysiology. J Headache Pain 2023; 24:34.
- Guo S, Jansen-Olesen I, Olesen J, Christensen SL. Role of PACAP in migraine: an alternative to CGRP? Neurobiol Dis 2023; 176:105946.
- And 2 more. Subscribe to see the full list
